Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (Glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis

Journal of Parasitology

Volumn 93, Issue 3, 2007, Pages 688-693

  Azeredo Coutinho, Rilza B Gayoso ^a   Mendonça, Sergio C F ^a   Callahan, Heather ^a,b   Portal, Andréia C ^a,b   Grögl, Max ^a,b,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b U S ARMY   (United States)

^c TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE;

DISEASE TREATMENT; DRUG; DRUG RESISTANCE; PROTOZOAN;

ARTICLE; BRAZIL; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; LOW DRUG DOSE; NONHUMAN; PROMASTIGOTE; RELAPSE; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; TREATMENT OUTCOME;

BRAZIL; RIO DE JANEIRO [BRAZIL]; SOUTH AMERICA;

LEISHMANIA BRAZILIENSIS; LEISHMANIA SP.;

EID: 34447119481     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-1031R.1     Document Type: Article

References (56)

1. AZEREDO-COUTINHO, R. B., AND S. C. F. MENDONÇA. 2002. An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 35: 477-481.
2. BATES, P. A., C. D. ROBERTSON, L. TETLEY, AND G. H. COOMBS. 1992. Axenic cultivation and characterization of Leishmania mexicana amastigote-like forms. Parasitology 105: 193-202.
3. BEHIN, R., J. MAUEL, AND B. SORDAT. 1979. Leishmania tropica: Pathogenicity and in vitro macrophage function in strains of inbred mice. Experimental Parasitology 48: 81-91.
4. 3H-formycin incorporation. Journal of Parasitology 70: 561-562.
5. _. 1988. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies. Reviews of Infectious Diseases 10: 560-586.
6. _, J. D. CHULAY, L. D. HENDRICKS, AND C. N. OSTER. 1982. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. American Journal of Tropical Medicine and Hygiene 31: 459-465.
7. _, AND D. J. WYLER. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. Journal of Infectious Diseases 142: 83-86.
8. BROCHU C., J. WANG, G. ROY, N. MESSIER, X. WANG, N. G. SARAVIA, AND M. OUELLETTE. 2003. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrobial Agents and Chemotherapy 47: 3073-3079.
9. BRYCESON, A. D. M. 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine and International Health 6: 928-934.
10. _, J. D. CHULAY, M. HO, M. MUGAMBI, J. B. WERE, R. MUIGAI, C. CHUNGE, G. GACHIHI, J. MEME, G. ANABWANI, AND S. M. BHATT. 1985. Visceral leishmaniasis unresponsive to antimonial drugs, I: Clinical and immunological studies. Transactions of the Royal Society of Tropical Medicine and Hygiene 79: 700-704.
11. CALLAHAN, H. L., AND S. M. BEVERLEY. 1991. Heavy metal resistance: A new role for P-glycoproteins in Leishmania. Journal of Biological Chemistry 266: 18427-18430.
12. _, C. KELLEY, T. PEREIRA, AND M. GROGL. 1996. Microtubule inhibitors: Structure-activity analyses suggest rational models to identify potentially active compounds. Antimicrobial Agents and Chemotherapy 40: 947-952.
13. _, A. C. PORTAL, R. DEVEREAUX, AND M. GROGL. 1997. An axenic amastigote system for drug screening. Antimicrobial Agents and Chemotherapy 41: 818-822.
14. CASTÉS, M., A. AGNELLI, O. VERDE, AND A. J. RONDON. 1983. Characterization of the cellular immune response in American cutaneous leishmaniasis. Clinical Immunology and Immunopathology 27: 176-186.
15. CHANG, K. P. 1980. Human cutaneous leishmania in a mouse macrophage line: Propagation and isolation of intracellular parasites. Science 209: 1240-1242.
16. CONVIT, J., M. E. PINARDI, AND A. J. RONDON. 1972. Diffuse cutaneous leishmaniasis: A disease due to an immunological defect of the host. Transactions of the Royal Society of Tropical Medicine and Hygiene 66: 603-610.
17. CROFT, S. L. 2001. Monitoring drug resistance in leishmaniasis. Tropical Medicine and International Health 6: 899-905.
18. _, S. SUNDAR, AND A. FAIRLAMB. H. 2006. Drug resistance in leishmaniasis. Clinical Microbiology Reviews 19: 111-126.
19. CUPOLILLO, E., L. R. BRAHIM, C. B. TOALDO, M. P. DE OLIVEIRA-NETO, M. E. DE BRITO, A. FALQUETO, M. DE FARIAS NAIFF, AND G. GRIMALDI JR. 2003. Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. Journal of Clinical Microbiology 41: 3126-3132.
20. _, G. GRIMALDI JR., AND H. MOMEM. 1994. A general classification of New World Leishmania using numerical zymotaxonomy. American Journal of Tropical Medicine and Hygiene 50: 296-312.
21. DE OLIVEIRA-NETO, M. P., M. S. MATTOS, M. A. PEREZ, A. M. DA-CRUZ, O. FERNANDES, J. MOREIRA, S. C. GONCALVES-COSTA, L. R. BRAHIN, C. R. MENEZES, AND C. PIRMEZ. 2000. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: Main clinical and epidemiologic characteristics. International Journal of Dermatology 39: 506-514.
22. DESJEUX, P. 2001. The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene 95: 239-243.
23. _ 2004. Leishmaniasis: Current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases. 27: 305-318.
24. EPHROS, M., A. BITNUN, P. SHAKED, E. WALDMAN, AND D. ZILBERSTEIN. 1999. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrobial Agents and Chemotherapy 43: 278-282.
25. GRIMALDI G. JR., AND R. B. TESH. 1993. Leishmaniasis of the New World: Current concepts and implications for future research. Clinical Microbiology Reviews 6: 230-250.
26. _, AND D. MCMAHON-PRATT. 1989. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. American Journal of Tropical Medicine and Hygiene 41: 687-725.
27. GROGL, M., M. J. A. ODUOLA, L. D. C. CORDERO, AND D. KYLE. 1989. Leishmania spp.: Development of pentostam-resistant clones in vitro by discontinuous drug exposure. Experimental Parasitology 69: 78-90.
28. _, T. N. THOMASON, AND E. D. FRANKE. 1992. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. American Journal of Tropical Medicine and Hygiene 47: 117-126.
29. HANDMAN, E., R. CEREDIG, AND G. F. MITCHELL. 1979. Murine cutaneous leishmaniasis: Disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages. Australian Journal of Experimental Biology and Medical Science 57: 9-29.
30. HEPBURN, N. C. 2001. Management of cutaneous leishmaniasis. Current Opinion in Infectious Diseases 14: 151-154.
31. IBRAHIM, M. E., M. HAG-ALI, A. M. EL-HASSAN, T. G. THEANDER, AND A. KHARAZMI. 1994. Leishmania resistant to sodium stibogluconate: Drug-associated macrophage-dependent killing. Parasitology Research 80: 569-574.
32. JACKSON, J. E., J. D. TALLY, W. Y. ELLIS, Y. B. MEBRAHTU, P. G. LAWYER, J. B. WERE, S. G. REED, D. M. PANISKO, AND B. L. LIMMER. 1990. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. American Journal of Tropical Medicine and Hygiene 43: 464-480.
33. JONES, T. C., W. D. JOHNSON JR., A. C. BARRETO, E. LAGO, R. BADARO, B. CERF, S. G. REED, E. M. NETTO, M. S. TADA, F. FRANCA, K. WIESE, L. GOLIGHTLY, E. FIKCRIG, J. M. L. COSTA, C. C. CUBA, AND P. D. MARSDEN. 1987. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. Journal of Infectious Diseases 156: 73-83.
34. KREUTZER, R. D., N. SOURATY, AND M. E. SEMKO. 1987. Biological identities and differences among Leishmania species and subspecies. American Journal of Tropical Medicine and Hygiene 36: 22-32.
35. LIRA, R., S. SUNDAR, A. MAKHARIA, R. KENNEY, A. GAM, E. SARAIVA, AND D. SACKS. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. Journal of Infectious Diseases 180: 564-567.
36. LLANOS-CUENTAS, E., P. D. MARSDEN, E. LAGO, A. BARRETO, C. CUBA, AND W. JOHNSON. 1984. Human mucocutaneous leishmaniasis in Três Braços, Bahia, Brazil - An area of Leishmania braziliensis braziliensis transmission, II: Cutaneous disease - Presentation and evolution. Revista da Sociedade Brasileira de Medicina Tropical 17: 169-177.
37. LOPES, U. G., H. MOMEN JR., G. GRIMALDI, M. C. A. MARZOCHI, R. PACHECO, AND C. M. MOREL. 1984. Schizodeme and zymodeme characterization of Leishmania in the investigation of foci of visceral and cutaneous leishmaniasis. Journal of Parasitology 70: 89-98.
38. LOUIS, J., A. GUMY, H. VOIGT, M. ROCKEN, AND P. LAUNOIS. 2002. Experimental cutaneous Leishmaniasis: A powerful model to study in vivo the mechanisms underlying genetic differences in Th subset differentiation. European Journal of Dermatology 12: 316-318.
39. _, I. HIMMELRICH, C. PARRA-LOPEZ, F. TACCHINI-COTTIER, AND P. LAUNOIS. 1998. Regulation of protective immunity against Leishmania major in mice. Current Opinion in Immunology 10: 459-464.
40. MARSDEN, P. D. 1985. Pentavalent antimonials: Old drugs for new diseases. Revista da Sociedade Brasileira de Medicina Tropical 18: 187-198.
41. _ 1986. Mucosal leishmaniasis ("espundia" Escomel, 1911). Transactions of the Royal Society of Tropical Medicine and Hygiene 80: 859-876.
42. MENDONÇA, S. C. F., S. G. COUTINHO, R. R. AMENDOEIRA, M. C. MARZOCHI, AND C. PIRMEZ. 1986. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: Lymphoproliferative responses and influence of therapy. Clinical and Experimental Immunology 64: 269-276.
43. _, W. J. S. SOUZA, M. P. NUNES, M. C. MARZOCHI, AND S. G. COUTINHO. 1988. Indirect immunofluorescence test in New World leishmaniasis: Serological and clinical relationship. Memórias do Instituto Oswaldo Cruz 83: 347-355.
44. MOREIRA, E. S., C. ANACLETO, AND M. L. PETRILLO-PEIXOTO. 1998. Effect of glucantime on field and patient isolates of New World Leishmania: Use of growth parameters of promastigotes to assess antimony susceptibility. Parasitology Research 84: 720-726.
45. MURRAY, H. W., J. D. BERMAN, C. R. DAVIES, AND N. G. SARAVIA. 2005. Advances in leishmaniasis. Lancet 366: 1561-1577.
46. OLIVEIRA-NETO, M. P., A. SCHUBACH, M. MATTOS, S. C. DA COSTA, AND C. PIRMEZ. 1997a. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - An area of Leishmania (V.) braziliensis transmission. International Journal of Dermatology 36: 463-468.
47. _, AND _. 1997b. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years). American Journal of Tropical Medicine and Hygiene 57: 651-655.
48. OUELLETTE, M., J. DRUMMELSMITH, AND B. PAPADOPOULOU. 2004. Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resistance Updates 7: 257-266.
49. PALACIOS, R., L. E. OSORIO, L. F. GRAJALES, AND M. T. OCHOA. 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to Leishmania Viannia species. American Journal of Tropical Medicine and Hygiene 64: 187-193.
50. ROBLEDO, S. M., A. Z. VALENCIA, AND N. G. SARAVIA. 1999. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment. Journal of Parasitology 85: 360-366.
51. ROMERO, G. A. S., M. V. F. GUERRA, M. G. PAES, AND V. O. MACÊDO. 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: Therapeutic response to meglumine antimoniate. American Journal of Tropical Medicine and Hygiene 65: 456-465.
52. SERENO, D., M. CAVALEYRA, K. ZEMZOUMI, S. MAQUAIRE, A. OUAISSI, AND J. L. LEMESRE. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrobial Agents and Chemotherapy 42: 3097-3102.
53. SHAKED-MISHAN, P., N. ULRICH, M. EPHROS, AND D. ZILBERSTEIN. 2001. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. Journal of Biological Chemistry 276: 3971-3976.
54. SUNDAR, S., AND M. RAI. 2002. Advances in the treatment of leishmaniasis. Current Opinion on Infectious Diseases 15: 593-598.
55. WALTON, B. C., J. SHAW, AND R. LAINSON. 1977. Observations on the in vitro cultivation of Leishmania braziliensis. Journal of Parasitology 63: 1118-1119.
56. WIJERS, D. J. B. 1971. A ten years' study of kala-azar in Tharaka (Meru district, Kenya). II: Relapses. East African Medical Journal 48: 551-558.